Salarius Pharmaceuticals announces Langer to join SAB

Decoy Therapeutics announces that Massachusetts Institute of Technology, MIT, Professor and Moderna co-founder Robert Langer, ScD will join the company’s Scientific Advisory Board, SAB, upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals (SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with the newly formed company to be named Decoy Therapeutics.